Back to top

iShares US Pharmaceuticals ETF (IHE) Implied Analyst Target Suggests Upside Toward $110

The iShares US Pharmaceuticals ETF (IHE) shows a 15.42% implied upside based on weighted analyst price targets, driven largely by high projections for smaller holdings like Omeros Corp, Wave Life Sciences, and Ocular Therapeutix. This upside, however, entails higher risk due to clinical and regulatory uncertainties..

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

iShares U.S. Pharmaceuticals ETF (IHE)